The productivity crisis in pharmaceutical R&D

Abstract

Advances in the understanding of the molecular basis of diseases have expanded the number of plausible therapeutic targets for the development of innovative agents in recent decades. However, although investment in pharmaceutical research and development (R&D) has increased substantially in this time, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging. Here, using a large database that contains information on R&D projects for more than 28,000 compounds investigated since 1990, we examine the decline of R&D productivity in pharmaceuticals in the past two decades and its determinants. We show that this decline is associated with an increasing concentration of R&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms. We also investigate the potential variations in productivity with regard to the regional location of companies and find that although companies based in the United States and Europe differ in the composition of their R&D portfolios, there is no evidence of any productivity gap.

Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease

“…For the last decade, pharmaceutical research and development productivity, measured by the relationship between investment input to develop new innovative drugs and the output/ outcome (e.g., medical and financial benefits resulting from the drug), dramatically deceased and, at the time of writing, remains low [1][2][3]. A number of factors contribute to the productivity issues in drug development, including increasing development costs, generic competition due to the patent expiry of several blockbuster drugs, increasingly conservative regulatory policies, and insufficient breakthrough innovations.…”

“…A number of factors contribute to the productivity issues in drug development, including increasing development costs, generic competition due to the patent expiry of several blockbuster drugs, increasingly conservative regulatory policies, and insufficient breakthrough innovations. Increasing research and development expenditures are more apparent in the disease indications with the highest unmet need, such as Alzheimer's disease (AD), where the attrition rate is high [1].…”

Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?

“…The amount of time it takes to get potential drugs and therapies from patenting to commercialization has increased over the years with average estimates now well over a decade (Pammolli, Magazzini, & Riccaboni, 2011). The costs of taking a product through the entire development process has also exponentially increased over the past decades, and now total costs are approximately $2 billion to take a product to the market (Munos, 2009).…”

Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy

“…1,2,3 Indeed, by some measures, productivity has not changed in 60 years. 4 High Throughput Screening (HTS) 5,6,7,8,9 is a well established and successful method for hit and lead discovery in pharmaceutical and biotechnology companies and increasingly now in academia.…”